NCT00833378View on ClinicalTrials.gov

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 19, 2009

Primary Completion Date

March 11, 2009

Study Completion Date

March 11, 2009

Conditions
Hepatitis C
Interventions
DRUG

Eltrombopag

Eltrombopag 100 mg single oral dose

DRUG

Lopinavir/Ritonavir

Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days

DRUG

Eltrombopag and Lopinavir/Ritonavir

Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY